US HHS Pulled Recommendation To Make Kratom A Controlled Substance, But Kept Mum On Change
Agency Recently Disclosed 2018 Letter To DEA Rescinding Findings To Schedule Kratom
HHS released to industry proponents Reps. Mark Pocan and Morgan Griffith the letter it submitted in 2018 notifying DEA that it was rescinding recommendation it made in 2017 to list kratom active ingredients mitragynine and 7-hydroxymitragynine under Schedule I of the CSA.
You may also be interested in...
FDA and FTC joint warnings to four kratom firms as well as an essential oil marketer explain they're acting under Department of Health and Human Services’ declaration of a public health emergency involving the opioid crisis.
American Kratom Association didn’t convince court to order FDA to extend to deadline for comments responding to World Health Organization’s question on whether kratom should be deemed controlled substances under UN schedule. Short comment period is “latest in what we think is a very hostile action” by FDA about kratom, says AKA executive Mac Haddow.
RFP states FDA "previously warned consumers about the use of Kratom (Mitragyna speciosa)” and although botanical’s “use is prevalent, to date, clinical evaluations of abuse potential have not been performed.”